[go: up one dir, main page]

WO2016053015A1 - Procédé de préparation d'aptamères ciblant de nouvelles cellules - Google Patents

Procédé de préparation d'aptamères ciblant de nouvelles cellules Download PDF

Info

Publication number
WO2016053015A1
WO2016053015A1 PCT/KR2015/010347 KR2015010347W WO2016053015A1 WO 2016053015 A1 WO2016053015 A1 WO 2016053015A1 KR 2015010347 W KR2015010347 W KR 2015010347W WO 2016053015 A1 WO2016053015 A1 WO 2016053015A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
selex
cell
aptamer
chip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/010347
Other languages
English (en)
Korean (ko)
Inventor
김소연
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Dongguk University
Original Assignee
Industry Academic Cooperation Foundation of Dongguk University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Dongguk University filed Critical Industry Academic Cooperation Foundation of Dongguk University
Publication of WO2016053015A1 publication Critical patent/WO2016053015A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers

Definitions

  • the present invention relates to a method for producing aptamer binding to a novel cell, specifically comprising culturing cells in a chip including a single or a plurality of chambers, and eluting the aptamer bound to the cells by treatment with an elution buffer. It relates to an aptamer manufacturing method.
  • Cell SELEX-on-a-chip was developed by applying microfluid to elute specific aptamer without damaging cells. Comparing Chip SELEX and conventional SELEX shows that SELEX can be efficiently performed on SELEX on SELEX-on-a-chip. It can be used to apply various cancer cell specific aptamers with excellent performance.
  • cancer is a representative disease that is difficult to treat completely. Most treatments require a combination of surgery and chemotherapy, but because it affects cells throughout the body, it is difficult to say that there is an appropriate treatment.
  • aptamers are in the spotlight in the treatment and diagnosis of cancer.
  • Aptamers are single stranded oligonucleotides that form specific three dimensional formation. Allows aptamers to have high affinity and specificity for the target molecule.
  • Aptamers have similar properties to antibodies but have a lower molecular weight, making them easier to synthesize in vitro and more stable at higher temperatures. In addition, the toxicity and antigenicity is lower.
  • Aptamers can be isolated by in vitro evolution processes such as SELEX (systematic evolution of ligands by exponential enrichment).
  • Target cells from 10 up to 14 - 10 15 random incubated with the ssDNA or RNA library comprising a nucleotide, then by washing the unbound sequence collect only the oligonucleotide bound to the cells.
  • a disadvantage of the conventional cell SELEX method is that the cells may be damaged in the elution step, which is caused by the fact that by-products from the cells can be obtained with bound aptamers because the cells are peeled off the plate.
  • a method is characterized by separating aptamers bound to cells without damaging the cells.
  • Chip SELEX is economical, effective and can perform faster. Since the chip has a small volume, it is possible to culture many different cells without contamination.
  • the present invention provides a method for producing aptamer that binds to a cell comprising the following steps: culturing the cell in a chip comprising a single or a plurality of chambers; Binding aptamer specific to the cell; Washing the cells to which the aptamer is bound; And eluting the aptamer bound to the cells by treatment with an elution buffer.
  • FIG. 1 shows the shape of a chip according to the invention.
  • Figure 2 shows a schematic diagram of a conventional SELEX and a chip SELEX according to the present invention.
  • FIG. 3 shows the incubation of Cy3 labeled aptamers with cells, (A): BNL 1ME A. 7R. Optical image of 1 cell, (B) BNL 1ME A. 7R after incubation with aptamer. Fluorescence image of 1 cell. Bound aptamers are eluted with the elution buffer and (C): BNL 1ME A. 7R. Optical image of 1 cell, (D) BNL 1ME A. 7R after incubation with elution buffer. An optical image of 1 cell is shown.
  • FIG. 4 is a graph showing normalized data of elution amount in a conventional SELEX and a chip SELEX according to the present invention.
  • the present invention relates to a method for producing aptamer that binds to a cell comprising the following steps: culturing the cell in a chip comprising a single or a plurality of chambers; Binding aptamer specific to the cell; Washing the cells to which the aptamer is bound; And eluting the aptamer bound to the cells by treatment with an elution buffer.
  • the method can separate aptamers bound to cells without damaging the cells.
  • Biomarkers such as antibodies, aptamers or peptides, can be used to diagnose a disease or to detect certain metabolites.
  • aptamer refers to a small single-stranded oligonucleotide that can specifically recognize a target with high affinity. Aptamers can be obtained by a specific method called SELEX (Systematic Evolution of Ligands by Exponential enrichment). In contrast to the target purified protein, Cell SELEX is used to select aptamers that target cell specific cells. Cell SELEX may be a better method because it can screen for aptamers that bind in vivo.
  • the conventionally used Cell SELEX has a large background problem, and in particular, by removing the whole cell instead of eluting the aptamer, a long round of SELEX was caused to obtain the aptamer.
  • Cell SELEX-on-a-chip was developed by applying a microfluid to elute specific aptamers without interfering with the cells. Comparing Chip SELEX and conventional SELEX shows that SELEX can be efficiently performed on SELEX on SELEX-on-a-chip. It can be used to apply various cancer cell specific aptamers with excellent performance.
  • the present invention has developed a method for efficiently improving conventional cell SELEX and cell SELEX-on-a-chip. Compared to conventional methods requiring large amounts of reagents and instruments, Ibidi® chips can run with much smaller volumes of reagents and cells. Moreover, through solution-based elution, contamination of DNA with cell debris prepared from the scraping method can be avoided. In terms of the efficiency of the new system, it is more than six times more efficient than the conventional Cell-SELEX method and can be used more efficiently to generate aptamers for markers such as cancer biomarkers.
  • Cell SELEX refers to a method for selecting aptamers having the highest binding ability to proteins or structures on the cell surface by performing SELEX on all living cells.
  • SELEX the development of aptamers for most cell surface receptors is accomplished using proteins purified by overexpression in E. coli.
  • the use of SELEX for live cells is because membrane proteins play an indispensable role in life, especially for cell signaling, growth and proliferation, and cell-cell interactions.
  • cancer cells cancerous mutations are caused by variations in the function of cancer receptors that affect expression levels or cancer progression.
  • Purified proteins recombinant proteins
  • aptamer selection which only binds to target positive cell lines. Since the cell surface has one or more receptors, the diversity of membrane proteins makes it difficult to screen for aptamers that target cancer proteins, and the selection takes about 10 rounds or more.
  • Positive and negative cell lines share a specific group of membrane proteins, which means that there is a high likelihood of choosing aptamers that can bind to both cell lines.
  • cell concentration and number of passages must be carefully controlled.
  • cell-SELEX as a biodiagnosis by incorporating fluorescent materials for diagnosis or treatment of tumors or using nanoparticles for drug delivery.
  • cancer diagnosis was judged by cell shape or tissue change, but there was an example of using aptamer, which selectively binds only Burkitt's lymphoma cells, with Cell-SELEX to diagnose cancer.
  • aptamers, nanoparticles, and control-release polymer systems to provide a platform for the selective treatment of cancer cells.
  • a novel cellular SELEX method has been developed that can elute aptamers without cell damage, and higher amounts of aptamers can be obtained.
  • the murine liver cancer cells BNL 1ME A.7R.1 cell line was used, which was obtained by transforming BNL CL.2 with methylcholanthrene epoxide, in which the TLS11 aptamer was converted to BNL 1ME A.
  • Targeting R7 cells is known.
  • experiments were carried out on conventional and novel methods using 100 mm and chips. The chip contains a smaller growth area than the 100 mm plate used in the prior art, so a smaller volume of reagent is sufficient.
  • an elution buffer was used to obtain bound aptamers (FIG. 2). This makes it possible to separate bound aptamers from cells without cell damage and separation. This method is expected to produce improved results in various aspects.
  • nucleic acid refers to single- or double-stranded DNA, RNA and chemical modifications thereof, which modifications do not interfere with the amplification of selected nucleic acids, but are not limited to, but are not limited to, backbone. Modification, methylation, biphasic combination, substitution of 5-bromo-uracil, and the like.
  • microfluidic device refers to a device capable of controlling or manipulating the flow of microscopic microscopic solutions, such as ⁇ l, nL, pL, fL, and the like.
  • the present invention provides an aptamer binding to a cell using a multiplex microfluidic device for nucleic acid aptamer selection that can be applied to an improved SELEX (Systematic Evolution of Ligands by Exponential Enrichment) process as shown in FIG. 1. It is about how to.
  • SELEX Systematic Evolution of Ligands by Exponential Enrichment
  • the multiplex microfluidic device used in the present invention has a great advantage over macro-scale cultures such as flasks, dishes and well-plates.
  • the flexibility in the design of the microfluidic device is great, which allows individual cell types to be tailored for the purpose and co-culture on the same chip.
  • microfluidic cell culture allows for reduced consumption of reagents, reduced risk of contamination and efficient high throughput experimentation.
  • the advantages of flexible design, single cell analysis, real-time on-chip analysis and low reagent consumption through time-lapse microscopy make microfluidic cell cultures more attractive for cell-SELEX applications. Make it suitable.
  • the chip herein may be a single or a plurality of chambers, for example ⁇ -slide (ibidi®), the shape of Figure 1 having a 0.6-2.5 cm 2 per channel growth area and 30-100ul channel volume May be a chip.
  • the single chamber may have a problem that the cells fall off a lot in the washing step, a plurality of chambers is preferable.
  • the chamber may comprise 1 ⁇ 10 5 ⁇ 9 ⁇ 10 5 cells.
  • the existing SELEX 5 ⁇ 10 6 cells were used, in the Chip SELEX 3 ⁇ 10 5 cells were used.
  • the chamber of the chip is small in volume, so the amount of cells required is small. About 10 5 cells per chamber is sufficient.
  • the cell culture may be performed at 37 °C.
  • the elution buffer may be at least one selected from the group consisting of MgCl 2 , NaCl, NaOH, and HCl, and preferably MgCl 2 .
  • the concentration of the buffer may be, for example, 5 mM to 5M, preferably 100 mM to 3M, more preferably 500 mM.
  • the elution buffer may be treated for 10 to 30 minutes, as confirmed in the embodiment, 30 minutes is the highest aptamer obtained concentration is preferred.
  • BNL.1.ME.7R.1 cells were purchased from the American Tissue Culture Collection (ATCC TIB-73), which is a murine hepatocellular carcinoma cell and transforms BNL CL.2 with methylcholanthrene epoxide. Induced.
  • a temperature test was performed to determine the conditions suitable for binding.
  • the cell SELEX binding is 4 °C, if too many cells are separated at 4 °C is carried out at 37 °C. Both conditions were tested. About 30-40% of the cells were separated from the chip surface at 4 ° C and only about 20% of the cells were separated at 37 ° C.
  • DNA elution buffers were tested at different concentrations based on HCl, NaOH, MgCl 2 or NaCl (HCl: 5 mM, 10 mM, 25 mM, 75 mM, 100 mM, 200 mM, 300 mM, 400).
  • NaOH 5 mM, 10 mM, 25 mM, 75 mM, 100 mM; NaCl: 50 mM, 100 mM, 500 mM, 1 M, 2 M, 3 M, 4 M; MgCl 2 : 100 mM, 500 mM , 1 M, 2 M, 3 M, 4 M, 5 M).
  • HCl 200 mM, 300 mM, 400 mM
  • NaCl 2 M, 3 M
  • MgCl 2 500 mM, 1 M.
  • 500 mM MgCl 2 was selected as the elution buffer.
  • HCl has a problem that the acid is too strong in the cell, NaCl concentration is too high than the concentration of MgCl 2 and showed similar performance for DNA elution.
  • the time required to elute DNA without cell damage was determined. After binding, cells were incubated with the elution buffer for 10, 20, or 30 minutes. Thereafter, the eluted DNA was quantified by RT-PCR. 3.34 ⁇ 10 6 , 9 ⁇ 10 7 , and 2 ⁇ 10 8 cells were obtained for 10, 20 and 30 minute elution times, respectively. Through this, it was confirmed that 30 minutes is the most appropriate elution time.
  • MgCl 2 in the elution buffer used for Chip SELEX, MgCl 2 , NaOH, NaCl, HCl, etc. were tested by concentration, but 500 mM MgCl 2 was selected because it can be used in experiments without damaging the cells. .
  • TLS11 aptamer 400 pmole of SELEX 5'-Cy3-labeled TLS11 aptamer (5'-cy3-ACGCTCGGATGCCACTACAGGCATCCCCATGTGAACAATCGCATTGTGATTGTTACGGTTTCCGCCTCATGGACGTGCTGGTGAC, Bioneer: SEQ ID NO: 1) was prepared. It has already been demonstrated that TLS11 aptamers target BNL 1ME A.7R.1 cells. Boil 5 minutes at 95 °C and cooled on ice for 3 minutes to form a secondary structure.
  • 5 ⁇ 10 6 cells were washed twice with 5 ml of wash buffer [5 mM MgCl 2 , 4.5 g glucose / L of DPBS], and then 5 ml binding buffer [4.5 g / L glucose, 5 mM MgCl containing 400 pmole of TLS11 aptamer] 2 , 0.1 mg / ml yeast tRNA, and 1 mg / mL bovine serum albumin (BSA) in DPBS] were added to the plate and bound for 30 min in a 37 ° C, 5% CO 2 incubator. After 30 minutes, the supernatant was removed and washed twice with 5 ml of wash buffer. The cells of the plate were then collected by scraping with wash buffer and centrifuged at 1000 rpm for 3 minutes. After that, the supernatant was removed and the pellet was freed with wash buffer.
  • wash buffer [5 mM MgCl 2 , 4.5 g glucose / L of DPBS]
  • Chip cell The SELEX ⁇ -slide chip contains six chambers. Since 3 pmole of aptamer (cy3-labeled TLS11 aptamer) is required for each chamber, a total of 18 pmole of aptamer was prepared. Boil 5 minutes at 95 °C and cooled on ice for 3 minutes to form a secondary structure. Each chamber contains 5 ⁇ 10 4 cells and was pre-washed twice with 30 ⁇ l wash buffer. Then, binding was performed by incubating at 37 ° C. for 30 min with a binding buffer in which aptamer (cy3-labeled TLS11 aptamer) was dissolved. At the end of the incubation, unbound aptamers were washed twice with 30 ⁇ l wash buffer and the supernatant collected in another tube. At this time, it was checked whether the aptamer is bound to each cell by fluorescence microscope.
  • RT-PCR real-time PCR
  • 20 ⁇ l of the mixture was made using Power SYBR Green PCR Mastermix (Applied Biosystems). 7 ⁇ L HPLC water, 10 ⁇ L 2x SYBR, 1 ⁇ L forward primer (ACG CTC GGA TGC CAC TAC AG, Bioneer: SEQ ID NO: 2) and reverse primer (GTC ACC AGC ACG TCC ATG AG, Bioneer: SEQ ID NO: 3), 1 ⁇ L Template aptamer.
  • the heating cycling protocol is as follows. Denaturation at 95 °C for 10 minutes, 95 °C 30 seconds ⁇ 52 °C 1 minutes ⁇ 72 °C 1 minutes This process was repeated 40 cycle. After amplification, the PCR product was liver inactivated at 95 ° C. for 15 seconds. The melting curve was analyzed from 52 ° C. to 95 ° C. with a temperature gradient of 0.3 ° C./s. Proceed to confirm that only a specific product will be amplified.
  • the cells were observed by fluorescence microscopy after binding, and the fluorescence signal was detected, thereby demonstrating that the aptamer labeled with cy-3 was attached to the surface of the cells.
  • the fluorescence signal was greatly reduced, thus confirming that the aptamer labeled cy-3 was successfully desorbed from the surface of the cells (FIGS. 3B, 3D).
  • the difference in efficiency between the chip cell SELEX and the existing cell SELEX was measured by quantitative analysis using RT-PCR. As shown in Table 1, 18 pmole (1.08 ⁇ 10 13 ) aptamer was used for the Chip SELEX, and 1.11 ⁇ 10 11 aptamer was eluted. As a conventional SELEX process, 2.4 ⁇ 10 14 aptamers were used to elute 4.07 ⁇ 10 11 aptamers. Therefore, it was confirmed that the chip selex according to the present invention used an aptamer about 22 times less. Regarding the aptamer extraction rate, the chip SELEX according to the present invention was proved more efficient than the conventional SELEX method.
  • Chip Cell SELEX and Chip Cell SELEX used different amounts of aptamer and normalized for more accurate calculation (FIG. 4). After normalization, it was confirmed that the Chip Cell SELEX according to the present invention obtained about 6.07 times more elute than the existing Cell SELEX method, which proved that the Chip Cell SELEX method according to the present invention is more efficient than the existing method.
  • Chip SELEX In experiments demonstrating the effectiveness of the new SELEX using Chip, 5 ⁇ 10 6 cells were used, 40 pmol of aptamer was used, and a total of 30.0 ml of buffer was used. Chip SELEX, on the other hand, used 3 ⁇ 10 5 cells, 10 pmol of aptamer, and 1.44 ml of buffer. Comparing the materials used in the experiments, Chip SELEX required 16 times fewer cells, 22 times less aptamers, and 21 times less buffer than conventional methods.
  • the aptamer can be obtained without using the elution buffer in the elution step without affecting the cells and by-products from the dead cells.
  • the Chip SELEX according to the present invention is economical, effective, and can be performed faster. Since the chip has a small volume, it is possible to culture various different cells without contamination. It may be preferred to culture hard to obtain cells or small amounts of cells.
  • Chip SELEX according to the present invention can be used for multiplex selection. Since the chip contains six chambers, it is possible to culture other cell lines without contamination. The chamber of the chip is small in volume, so the amount of cells required is small. About 10 5 cells per chamber is sufficient.
  • the present invention instead of scraping and separating the cells, only the bound aptamer is separated using the elution buffer, so that the aptamer bound to the cells can be separated without damaging the cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à un procédé de préparation d'aptamères se liant à de nouvelles cellules et, plus précisément, à un procédé de préparation d'aptamères, comprenant une étape consistant à éluer des aptamères liés à des cellules par la culture de cellules dans une puce comprenant une seule chambre ou une pluralité de chambres et le traitement de ces dernières avec un tampon d'élution. Une méthode SELEX de cellules sur puce a été développée par application d'un microfluide pour l'élution d'aptamères spécifiques sans endommagement des cellules. Il est montré que la méthode SELEX peut être efficacement mise en œuvre dans une méthode SELEX sur puce, par comparaison avec une méthode SELEX à puce et une méthode SELEX classique. Il est montré que le procédé, qui a une excellente performance, peut être appliqué à des aptamères spécifiques de diverses cellules cancéreuses.
PCT/KR2015/010347 2014-09-29 2015-09-30 Procédé de préparation d'aptamères ciblant de nouvelles cellules Ceased WO2016053015A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140130412 2014-09-29
KR10-2014-0130412 2014-09-29

Publications (1)

Publication Number Publication Date
WO2016053015A1 true WO2016053015A1 (fr) 2016-04-07

Family

ID=55630966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/010347 Ceased WO2016053015A1 (fr) 2014-09-29 2015-09-30 Procédé de préparation d'aptamères ciblant de nouvelles cellules

Country Status (2)

Country Link
KR (1) KR101849557B1 (fr)
WO (1) WO2016053015A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100044787A (ko) * 2007-07-17 2010-04-30 소마로직, 인크. 개선된 오프―레이트를 갖는 압타머를 생성하는 방법
KR20100129709A (ko) * 2009-06-01 2010-12-09 성균관대학교산학협력단 췌장암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
US20110129850A1 (en) * 2006-12-22 2011-06-02 UCLA Office of Intellectual Property Microfluidic platform for cell culture and assay
KR20120035893A (ko) * 2010-10-05 2012-04-16 피씨엘 (주) 핵산 압타머 선별을 위한 멀티플렉스 미세 유체 장치 및 이를 이용한 핵산 압타머의 고속 선별방법
KR20140013107A (ko) * 2014-01-03 2014-02-04 충북대학교 산학협력단 비브리오 파라해모라이티쿠스 생균의 표면에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312085B2 (en) 2002-04-01 2007-12-25 Fluidigm Corporation Microfluidic particle-analysis systems
EP2329045A4 (fr) 2008-08-15 2012-09-19 Univ Cornell Dispositif pour une identification rapide d'acides nucléiques pour une liaison à des cibles chimiques spécifiques
TW201326814A (zh) 2011-12-21 2013-07-01 Nat Univ Tsing Hua 篩選細胞適合體之微流體晶片裝置及其方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129850A1 (en) * 2006-12-22 2011-06-02 UCLA Office of Intellectual Property Microfluidic platform for cell culture and assay
KR20100044787A (ko) * 2007-07-17 2010-04-30 소마로직, 인크. 개선된 오프―레이트를 갖는 압타머를 생성하는 방법
KR20100129709A (ko) * 2009-06-01 2010-12-09 성균관대학교산학협력단 췌장암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
KR20120035893A (ko) * 2010-10-05 2012-04-16 피씨엘 (주) 핵산 압타머 선별을 위한 멀티플렉스 미세 유체 장치 및 이를 이용한 핵산 압타머의 고속 선별방법
KR20140013107A (ko) * 2014-01-03 2014-02-04 충북대학교 산학협력단 비브리오 파라해모라이티쿠스 생균의 표면에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도

Also Published As

Publication number Publication date
KR20160037818A (ko) 2016-04-06
KR101849557B1 (ko) 2018-04-17

Similar Documents

Publication Publication Date Title
Afshar et al. Transcriptional drifts associated with environmental changes in endothelial cells
CN110669826A (zh) 通过顺序杂交编条形码的分子多重标记
CN110100010A (zh) 单细胞中细胞内或表面分子靶标的多重检测
WO2016162997A1 (fr) Système d'analyse de gène
CN109913539A (zh) 一种靶向捕获hla基因序列并测序的方法
CN107513576A (zh) 一种用于检测遗传性心肌疾病的试剂盒及其应用
EP4392176A1 (fr) Dosage d'interaction cellule-cellule régulée
Cho et al. Seq-Scope: Submicrometer-resolution spatial transcriptomics for single cell and subcellular studies
CN105985962A (zh) 特异性靶向类风湿关节炎炎性滑膜细胞的适配子及其应用
WO2018117333A1 (fr) Ensemble biosonde permettant une auto-amplification de signal de fluorescence afin de détecter l'arnmicro et son utilisation
CN111635936A (zh) 检测人染色体数目的探针组合物、试剂盒和应用
CN106282361B (zh) 用于捕获血液病相关基因的基因捕获试剂盒
CN106282191B (zh) 特异性靶向骨肉瘤细胞的适配子及其制备方法和应用
WO2016053015A1 (fr) Procédé de préparation d'aptamères ciblant de nouvelles cellules
US11427825B2 (en) Functional ligands to drug compounds
US10676781B2 (en) Functional ligands to THC
CN105331693A (zh) 对类志贺邻单胞菌8种o抗原分型的基因液相芯片及检测方法
US7297520B2 (en) Large circular sense molecule array
CN117467782A (zh) 一种生殖道感染病原体的恒温荧光检测系统
US10927381B2 (en) Functional ligands to LL37
CN108103178A (zh) 血液肿瘤融合基因的高通量检测试剂盒及检测方法
US10941444B2 (en) Functional ligands to lipoarabinomannan
US12091775B2 (en) RNA structure library
CN107586847B (zh) 一种环形接头及其应用
US20240110237A1 (en) Functional ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15847542

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15847542

Country of ref document: EP

Kind code of ref document: A1